Anti-Mouse PD-L1 [Clone 10F.9G2] — Purified in vivo GOLD™ Functional Grade

Clone 10F.9G2 is a rat monoclonal antibody specific for mouse PD-L1 (CD274, B7-H1), and it is widely used in in vivo mouse studies to block PD-L1-mediated immune checkpoint signaling. Its principal applications are to investigate and manipulate immune responses—particularly anti-tumor activity and autoimmune phenomena—by inhibiting the interaction of PD-L1 with its receptors.

Key in vivo applications:

• Blocking PD-L1 interactions: 10F.9G2 is used to disrupt PD-L1 binding to PD-1 and B7-1 (CD80), both of which are critical for immune regulation. By blocking these interactions, it can relieve immune suppression and enhance T cell-mediated responses against tumors or in autoimmune disease models.
• Cancer immunotherapy research: In mouse models of melanoma and other cancers, administration of 10F.9G2 can transiently arrest tumor growth. This occurs because PD-L1 blockade encourages cytotoxic T cell activity against tumor cells, diminishing the tumor’s ability to evade immune surveillance.
• Autoimmunity studies: It has been used to accelerate disease onset and severity in models of T cell-driven autoimmunity, such as the NOD mouse model for type 1 diabetes. Administration of 10F.9G2 in these models increased infiltration of CD8+ T cells into pancreatic islets and boosted diabetes incidence and severity.
• Functional receptor-ligand analysis: The antibody is also applied to probe the in vivo roles of PD-L1 across various immune cell types, including T and B cells, NK cells, and dendritic cells.

Additional Uses:

• While in vivo blocking is its main purpose, 10F.9G2 is also utilized in flow cytometry, immunofluorescence, and other functional assays to monitor PD-L1 expression and immune cell dynamics.

Mechanistic context:PD-L1 binding to PD-1 on T cells normally inhibits their proliferation and cytokine production—a mechanism exploited by tumors and contributing to immune tolerance. Blocking this checkpoint unleashes T cell responses, which is foundational for checkpoint inhibitor therapies.

Summary Table: Use of Clone 10F.9G2 in Mouse Studies

10F.9G2 remains the most widely used PD-L1-blocking antibody in mouse in vivo studies, especially in fields of cancer immunology and autoimmunity.

The correct storage temperature for sterile packaged clone 10F.9G2 (anti-mouse PD-L1) is 2-8°C (refrigerated, typically 4°C) and it should not be frozen for short-term storage.

• Bio X Cell (a primary supplier for in vivo grade monoclonal antibodies) specifies: “The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.”
• Other suppliers confirm: for up to 1 month, store at 2-8°C; for longer term storage (more than 3 months), aliquot and store at ? -70°C (do not subject to repeated freeze-thaw cycles).
• Always refer to the specific lot datasheet provided with your product, as formats or stabilizers can slightly alter storage recommendations.

In summary:

• Short-term (up to 1 month): Store at 2-8°C (refrigerator). Do not freeze.
• Long-term (over 3 months): Store aliquots at -70°C.

Commonly used antibodies or proteins alongside 10F.9G2 (an anti-mouse PD-L1/B7-H1 antibody) in the literature often include those targeting other immune checkpoint pathways or immune cell markers. Key examples include:

• Anti-PD-1 antibody (clone 29F.1A12): This targets the PD-1 receptor, frequently paired with 10F.9G2 to study the PD-1/PD-L1 axis and compare blocking capacity and function in murine models.
• Anti-PD-L1 antibody (clone 10F.2H11): Another anti-PD-L1 monoclonal antibody frequently used as a comparator for 10F.9G2, with the distinction that 10F.2H11 specifically blocks PD-L1:B7-1 interactions but not PD-L1:PD-1, while 10F.9G2 blocks both.
• Isotype controls (e.g., Rat IgG2b): Used as negative controls to validate specificity and account for background staining in assays.
• Immune cell subset markers: Commonly paired with 10F.9G2 in flow cytometry or immunohistochemistry for immune profiling. Examples include:
  • Anti-CD4 (T helper cell marker)
  • Anti-CD8 (cytotoxic T cell marker)
  • Anti-CD45 (pan-leukocyte marker)
  • Anti-CD3 (pan-T cell marker)

In summary, 10F.9G2 is most commonly used in conjunction with antibodies against PD-1, alternative PD-L1 clones, and immune cell lineage markers, especially for studies exploring immune checkpoint regulation and immune infiltrate characterization in mouse models.

Clone 10F.9G2 is a rat monoclonal antibody targeting mouse PD-L1 (CD274) that serves as a widely used research tool for blocking PD-L1 interactions and investigating immune regulation in cancer and autoimmune models.

Key findings from scientific literature citing 10F.9G2 include:

• Dual blockade: Unlike 10F.2H11, 10F.9G2 blocks both PD-L1:PD-1 and PD-L1:B7-1 interactions by recognizing a unique epitope on PD-L1, demonstrated via in vitro adhesion assays and blocking experiments. Its dual-blocking activity distinguishes it from antibodies that target only one interaction, contributing to its versatility in studying PD-L1 biology.
• Epitope specificity: 10F.9G2 does not compete for binding with 10F.2H11 (another anti-PD-L1 mAb), confirming it recognizes a distinct non-overlapping epitope. It does, however, compete with clone MIH5, suggesting that 10F.9G2 and MIH5 target similar sites on PD-L1 critical for effector functions.
• Tumor inhibition: In mouse models, treatment with 10F.9G2 significantly inhibits tumor growth compared to PBS controls. While peptide vaccines targeting PD-L1 sometimes outperform 10F.9G2, both approaches have shown efficacy in prolonging survival and reducing tumor volumes in syngeneic mouse models (e.g., 4T1, D2F2, CT26).
• Application profile: 10F.9G2 is validated for use in flow cytometry, immunohistochemistry, and functional in vivo blockade experiments to study PD-L1-mediated immune regulation.

In summary: 10F.9G2 is recognized for its ability to interrupt both major PD-L1-mediated immune checkpoint pathways, making it a highly cited antibody in studies dissecting immune escape, antitumor immunity, and autoimmune mechanisms in mice.